Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 17, 2024

BUY
$22.72 - $29.68 $823,690 - $1.08 Million
36,254 New
36,254 $1.05 Million
Q1 2023

Apr 18, 2023

SELL
$34.93 - $42.03 $3.95 Million - $4.75 Million
-113,121 Reduced 67.33%
54,889 $1.99 Million
Q4 2022

Jan 12, 2023

BUY
$31.09 - $37.88 $3.91 Million - $4.77 Million
125,795 Added 297.99%
168,010 $5.99 Million
Q2 2022

Jul 27, 2022

BUY
$25.33 - $34.25 $1.07 Million - $1.45 Million
42,215 New
42,215 $1.22 Million
Q1 2022

Apr 25, 2022

SELL
$28.51 - $32.9 $1.98 Million - $2.28 Million
-69,389 Closed
0 $0
Q4 2021

Feb 01, 2022

BUY
$26.37 - $34.22 $1.83 Million - $2.37 Million
69,389 New
69,389 $2.02 Million
Q1 2019

Apr 26, 2019

SELL
$32.77 - $41.99 $219,624 - $281,416
-6,702 Closed
0 $0
Q4 2018

Jan 23, 2019

BUY
$30.84 - $49.51 $206,689 - $331,816
6,702 New
6,702 $223,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $2.14B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.